Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
- 19 March 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 8 (4) , 541-553
- https://doi.org/10.1517/14712598.8.4.541
Abstract
Background: Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies. Malignant gliomas are amongst the mo...Keywords
This publication has 137 references indexed in Scilit:
- A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MRNeuroImage, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Combined Vascular Endothelial Growth Factor–Targeted Therapy and Radiotherapy for Rectal Cancer: Theory and Clinical PracticeSeminars in Oncology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Integrin signalling during tumour progressionNature Reviews Molecular Cell Biology, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971